Evaluation of a pretest scoring system (4Ts) for the diagnosis of heparin-induced thrombocytopenia in a university hospital setting

Postgraduate Medicine

Volumn 124, Issue 6, 2012, Pages 36-42

  Vatanparast, Rodina ^a   Lantz, Sarah ^a   Ward, Kristine ^a   Crilley, Pamela Ann ^a   Styler, Michael ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

4Ts; Heparin induced thrombocytopenia; Pretest; Scoring system

Indexed keywords

HEPARIN; THROMBIN INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRETEST SCORING SYSTEM; PROBABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOSIS; UNITED STATES; VALIDATION STUDY; CHEMICALLY INDUCED DISORDER; DECISION SUPPORT SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; MIDDLE AGED; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL;

AGED; DECISION SUPPORT TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARIN; HOSPITALS, UNIVERSITY; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

MLCS; MLOWN;

EID: 84875761550     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.11.2611     Document Type: Article

References (35)

1. Linkins LA, Dans AL, Moores LK, et al; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e495S-e530S.
2. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82(2):439-447.
3. Stanton PE Jr, Evans JR, Lefemine AA, et al. White clot syndrome. South Med J. 1988;81(5):616-620.
4. Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T's score. J Thromb Haemost. 2010;8(7):1483-1485.
5. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92(2):494-497.
6. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127(5):1857-1861.
7. Chong BH, Castaldi PA. Platelet proaggregating effect of heparin: possible mechanism for non-immune heparin-associated thrombocytopenia. Aust N Z J Med. 1986;16(5):715-716.
8. Van der Linden T, Souweine B, Dupic L, Soufir L, Meyer P. Management of thrombocytopenia in the ICU (pregnancy excluded). Ann Intensive Care. 2012;2(1):42.
9. Ohman EM, Granger CB, Rice L, et al; Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. J Thromb Thrombolysis. 2005;19(1):11-19.
10. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809-817.
11. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715.
12. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644-1649.
13. Oliveira GB, Crespo EM, Becker RC, et al; Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008;168(1):94-102.
14. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9):2937-2941.
15. Warkentin TE, Eikelboom JW. Who is (still) getting HIT? Chest. 2007;131(6):1620-1622.
16. Junqueira DR, Perini E, Penholati RR, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2012;9:CD007557.
17. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708.
18. Nader ND, Khadra WZ, Reich NT, Bacon DR, Salerno TA, Panos AL. Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg. 1999;68(5):1640-1643.
19. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost. 2010;8(1):30-36.
20. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79(1):1-7.
21. Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH; Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost. 2011;9(12):2498-2500.
22. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol. 2007;82(12):1037-1043.
23. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312.
24. Lo GK, Juhl D, Warkentin TE, Siqouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
25. Lillo-Le Louët A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost. 2004;2(11):1882-1888.
26. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8(12):2642-2650.
27. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis [published online ahead of print September 18, 2012]. Blood.
28. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95(1):161-167.
29. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30.
30. Trehel-Tursis V, Louvain-Quintard V, Zarrouki Y, Imbert A, Doubine S, Stéphan F. Clinical and biologic features of patients suspected or confrmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU [published online ahead of print March 8, 2012]. Chest.
31. US Food and Drug Administration. Drugs to be discontinued. http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050794.htm. Updated October 11, 2012. Accessed October 17, 2012.
32. Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011:143-149.
33. Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L. A randomized, open-label pilot study comparing desirudin and argatro-ban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther. 2011; 18(1):14-22.
34. Multz AS, Lisker GN. The management of suspected heparin-induced thrombocytopenia in US hospitals [published online ahead of print August 14, 2012]. Clin Appl Thromb Hemost.
35. Smythe MA, Koerber JM, Mehta TP, et al. Assessing the impact of a heparin-induced thrombocytopenia protocol on patient management, outcomes and cost. Thromb Haemost. 2012;108(5):992-998.